Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination - Wikidata - wikimedia - TriplyDB

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

http://www.wikidata.org/entity/Q34033823

about

HPV prophylactic vaccination in males improves the clearance of semen infection.Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.Functional assessment and structural basis of antibody binding to human papillomavirus capsid.A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model.Escherichia coli-derived virus-like particles in vaccine development.

P2860

Q36252874-4CF0E4EA-CD2D-4467-AF4E-D3CEA0CD8582 Q36846030-A9E27960-6961-4C08-92B2-9C7A6B601894 Q38671633-E4AE78CF-5045-4E8D-9030-E7D27226AD79 Q40129472-8D4BF3E9-26F9-4094-845B-776BED01FB94 Q47132009-62080ACD-77E0-4AE5-87B8-9EB44320DD4F

P2860

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

http://www.wikidata.org/entity/Q34033823

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Correlation between ELISA and ...... al infection or by vaccination

@ast

Correlation between ELISA and ...... al infection or by vaccination

@en

Correlation between ELISA and ...... al infection or by vaccination

@nl

type

label

Correlation between ELISA and ...... al infection or by vaccination

@ast

Correlation between ELISA and ...... al infection or by vaccination

@en

Correlation between ELISA and ...... al infection or by vaccination

@nl

prefLabel

Correlation between ELISA and ...... al infection or by vaccination

@ast

Correlation between ELISA and ...... al infection or by vaccination

@en

Correlation between ELISA and ...... al infection or by vaccination

@nl

P1433

Q34033823-14DBE270-D1EB-4436-B027-212C470FE1B1

P1476

Q34033823-3EB21B7A-81C9-4B05-9EFF-91D38F2106D7

P2093

Q34033823-06488A33-1B03-4C6A-824D-2CB3530C0213

Q34033823-14F0A75C-9180-4BD2-A771-8E0E4F434582

Q34033823-29D26044-8068-4102-9A96-83A981FE74B8

Q34033823-504B11DF-CDDA-492E-AF62-9251F13FCDA6

Q34033823-6C0D9DAE-6501-4544-8FA8-998F62842A01

Q34033823-9B44A8CB-FF32-41C8-A5C0-6EAEEAF5C092

Q34033823-AC289FBF-E991-41BD-9BD2-D7028ECAE31A

Q34033823-C5DE6310-780B-4229-9ACF-EDA4170605DA

Q34033823-EEA76CB0-6343-4EBE-9848-467DB5F28397

Q34033823-FDA934D1-0DE0-431C-82DD-13A25047436E

P2860

Q34033823-18E5E4EF-23B3-41C6-BCEF-CB417C48056C

Q34033823-1A2B26DF-0015-495C-87FF-9E8FCD73DE0F

Q34033823-26B4A0B1-4544-4F20-A51F-BC80B6D3DA73

Q34033823-4461E833-9498-4779-A81B-BD23493ED2A3

Q34033823-4B30A445-3C19-4F17-ABE5-46EB8B33CF30

Q34033823-5E144DC8-65F0-4A16-8918-D0D33EE824A1

Q34033823-6B2267BB-D2FA-4E8A-895C-119F2E2B8F60

Q34033823-6EE9F241-2142-43AC-9AEA-BCB357596E12

Q34033823-705B449D-EB17-4139-91F6-229904F55CA2

Q34033823-88898948-9AE0-48E8-AA14-59F67E5D2C18

P304

Q34033823-58C1107C-0681-4211-AD21-4DE7808E990A

P31

Q34033823-0223DAF6-6EE0-41D0-BE7F-2AE9898F105F

P356

Q34033823-E0F64BA2-CDC1-4605-89DF-706D0B0CBE28

P433

Q34033823-130F6396-4CD0-42F4-AC84-170D00F6D8C1

P478

Q34033823-D3B7185D-0B88-4120-883F-E0427C43A84A

P50

Q34033823-F5E51404-6725-4207-ACCE-B2EEF5BF3DEA

P577

Q34033823-31ABBE54-19BD-49E6-B06D-55F76C4E9A3E

P5875

Q34033823-B61C0056-38C4-4E52-A4A2-A742E291C238

P698

Q34033823-2B13D067-48B2-4916-AF32-0AE8CA5E3FF6

P921

Q34033823-3032A728-5B1F-497D-B042-AA4D04A22576

P932

Q34033823-C52E8CD9-F6E4-458B-8393-18D402398D3B

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

Correlation between ELISA and ...... al infection or by vaccination

@en

P2093

Chang-Gui Li

http://www.w3.org/2001/XMLSchema#string

Hui Zhao

http://www.w3.org/2001/XMLSchema#string

Hui-Rong Pan

http://www.w3.org/2001/XMLSchema#string

Juan Li

http://www.w3.org/2001/XMLSchema#string

Jun Zhang

http://www.w3.org/2001/XMLSchema#string

Meng Guo

http://www.w3.org/2001/XMLSchema#string

Ning-Shao Xia

http://www.w3.org/2001/XMLSchema#string

Shou-Jie Huang

http://www.w3.org/2001/XMLSchema#string

Xiao-Hui Liu

http://www.w3.org/2001/XMLSchema#string

Zhi-Jie Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Papillomaviruses and cancer: from basic studies to clinical application

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

P304

740-746

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.27619

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259566261

http://www.w3.org/2001/XMLSchema#string

P698

24384608

http://www.w3.org/2001/XMLSchema#string

P921

P932

4130265

http://www.w3.org/2001/XMLSchema#string